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Consider a genomic signature to be a set of genes whose measured expression
is transformed into a prediction of an outcome of interest. Such signatures are
the bases of a set of FDA-approved medical tests for predicting the risk of distal
recurrence and differential survival in breast cancer patients [84, 83, 63]. The
goal of these tests is to provide clinicians with an additional piece of prognostic
information that may affect their decision making pertaining to the treatment of
a breast cancer patient. As it stands, the tests based on these genomic signatures
(MammaPrint, Oncotype DX, Prosigna) are not part of the standard of care for
a patient, and there are many issues in the translation of these discoveries from
bench to bedside that hinder their reliable use [24]. These issues range from
insufficiently thorough validation [86], to technical errors or oversights [5, 46],
to outright retraction of results [75].
In addition to the lack of impact in clinical practice, the difficulty of trans-
lating these genomic discoveries represents uncertainty about the viability of
clinical genomics in general. The vast majority of genetic quantities that are
routinely evaluated for a patient were discovered and characterized prior to the
1
era of high-throughput genomics, e.g. [28, 88, 77, 34, 51]. Although there have
been one-off successes [89] and a wide range of candidate and pathway discover-
ies [85], the costs have been great relative to the payout in terms of widespread
clinical use [14]. By examining issues at the point of translation, we can begin
to provide a clearer picture of what is possible and realistic to accomplish in
the clinic with the discoveries that we have from the high-thorughput era.
Here, we examine two prominent issues in the translation of genomic sig-
natures for risk prediction in breast cancer: reproducibility/replicability and
assessment of value added. We address questions of reproducibility and repli-
cability at three levels:
1. on the reproducibility of predictions from a genomic signature-based pre-
dictor (Chapter 2). In this chapter, we introduce the notion of “test set
bias”, which occurs when a genomic signature that has been trained on
one dataset is applied to make predictions on another dataset. Due to
underlying calculations of distance between gene expression profiles in the
process of assigning a risk classification for a particular patient, the test
set data require pre-processing and normalization prior to application of
the predictive model. We show that this can cause the same patient to
receive a different classification depending upon the number and makeup
of the patients their profile is normalized with, even though there is no
underlying biological change in the patient themselves.
2. on the reproducibility of the process of building a predictive model with
gene expression data (Chapter 3). We propose one alternative to gene
signature building that avoids the issue of test set bias introduced in
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Chapter 2. This process uses rank-based features called Top-Scoring Pairs
(TSPs) [79], and we describe novel feature selection and model-building
approaches to produce fast, interpretable TSP-based gene signatures. We
address the issue of reproducibility of the model-building process by de-
scribing the tdsm R package, which intends to make the general appli-
cation of a statistical analysis transparent and well-documented. This is
accomplished with prefabricated analysis templates written in R Mark-
down which restrict user manipulation of parameters and settings.
3. on the distinction between reproducibility and replicability as it pertains
to scientific studies (Chapter 5). In this chapter, we examine the issue of
replicability. While reproducibility refers to applying the same procedure
to the same data and producing the same result [67, 68], replicability (of
a study) refers to running a new experiment to address the same scientific
question and seeing a result consistent with a previous study [4, 42]. We
promote the use of 95% prediction intervals as one way to determine if
an effect estimated from a study replication is consistent with the effect
estimated in the original study. Although this is done with respect to
studies in psychology, the conceptual framework regarding what to expect
when a study is replicated can be applied to the realm of validation and
confirmation studies that are commonly required for genomic signatures.
The second major topic is the question of the value that a prediction from a
genomic signature provides. A risk prediction or classification from a genomic
test may be inconclusive or may provide information redundant with what a
doctor has already surmised from standard clincial quantities. It is well-known
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that doctors send out for genomic tests for a variety of reasons and for a large
variety of patients [24]. As a result, determining whether the prediction from
a test helped the patient is not as simple as looking at the patient’s outcome.
For example, if the doctor ignored the prediction from the genomic test and the
patient had a good outcome, the outcome ought not be attributed to the test
result. We therefore address the question of value by considering how much ad-
ditional information the prediction from a genomic test could provide a clinician
conditional on the clinical quantities already at hand. We approach this in the
realm of randomized clinical trials (RCTs), where we have more control over
experimental design and a direct method for assessing value added. In Chapter
4, we describe a set of RCT simulations based on a real breast cancer dataset.
In this setting, we have available a between-arm treatment effect estimator that
can yield improved precision by adjusting for predictive covariates at baseline
[21]. Through simulation, we determine how much additional precision we gain
by adjusting for different sets of baseline covariates as compared to the basic,
unadjusted treatment effect estimator. We are able to then approximate how
much additional precision we would stand to gain were we to adjust for the
prediction from a genomic test in addition to a set of baseline covariates that a
clinician would consider. We find that there is minimal additional gain, repre-
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Motivation: Prior to applying genomic predictors to clinical samples, the ge-
nomic data must be properly normalized to ensure that the test set data are
comparable to the data upon which the predictor was trained. The most ef-
fective normalization methods depend on data from multiple patients. From a
biomedical perspective, this implies that predictions for a single patient may
change depending on which other patient samples they are normalized with.
This test set bias will occur when any cross-sample normalization is used before
clinical prediction.
Results: We demonstrate that results from existing gene signatures which
rely on normalizing test data may be irreproducible when the patient population
changes composition or size using a set of curated, publicly-available breast
cancer microarray experiments. As an alternative, we examine the use of gene
signatures that rely on ranks from the data and show why signatures using
7
rank-based features can avoid test set bias while maintaining highly accurate
classification, even across platforms.
Availability:The code, data, and instructions necessary to reproduce our
entire analysis is available at https://github.com/prpatil/testsetbias.
2.2 Introduction
One of the most common barriers to the development and translation of genomic
signatures is cross-sample variation in technology, normalization, and laborato-
ries [53]. Technology, batch, and sampling artifacts have been responsible for
the failure of genomic signatures [69, 5], irreproducibility of genomic results [59],
and retraction of papers reporting genomic signatures [75]. Even highly success-
ful signatures such as Mammaprint [84] have required platform-specific retrain-
ing before they could be translated to clinical use [33]. An under-appreciated
source of bias in genomic signatures is test set bias [52]. Test set bias occurs
when the predictions for any single patient depend on the data for other pa-
tients in the test set. For example, suppose that the gene expression data for
a single patient is normalized by subtracting the mean expression and dividing
by the standard deviation of the expression across all patients in the test set.
Then the normalized value for any specific gene for that patient depends on the
values for all the patients they are normalized with. The result is that a patient
may get two different predictions using the same data and the same prediction
algorithm, depending on the other patients used to normalize the test set data
(Figure 2.1).
There are many scenarios under which a patient’s classification ought to
8
change: if new information updates or alters the prediction algorithm, or if the
raw, biological patient data itself changes. The case we would like to explore is
when the gene signature and prediction algorithm are “locked down” and when
there is no biological variation in the patient data. We are concerned with
how much data transformation due to pre-processing and normalization affects
classification. It is our assertion that steps taken to transform patient data for
the purposes of applying a prediction algorithm should not alter the patient’s
eventual classification.
Some normalization methods [57, 70, 11] and some batch correction methods
[47, 62] have addressed this issue by normalizing each sample against a fixed, or
”frozen”, set of representative samples. Unfortunately, these approaches can be
applied only to specific platforms where large numbers of representative samples
have been collected. This is especially relevant when custom chips are designed,
as is the case in many clinical applications. There remain a large range of
platforms for measuring gene expression in use by researchers [9], and single
sample normalization methods are not currently available for many of these
platforms. Additionally, methods such as quantile normalization and other
forms of data scaling and transformation have become well-known in the field
and are often applied as standard steps in a data processing pipeline.
Even if single sample normalization methods were universally available, pub-
lic measures of gene expression are frequently pre-processed using a range of
methods for cleaning, normalization, and analysis, resulting in a range of expres-
sion values for the same gene across different platforms [1]. A more tractable
solution is to build gene signatures that do not rely on raw gene expression
values. We propose using the ranks of genes instead of their raw expression
9
Figure 2.1: A description of how test set bias can alter class prediction
for an individual patient. In panel a), we learn a model for predicting if a
patient is in class R (red) or class B (blue). In our training data, the patients
with darker grey features tend to be in class B, while the lighter grey patients
are in class R. We develop a prediction rule from our training data and apply
it to a new darker grey patient, and we see that he is likely to be classified to
class B. In panel b), we attempt to classify a single patient in the context of two
different patient populations. We see that depending on the number and type
of other patients in the population when we normalize the data, the resulting
feature profile for our patient can be drastically different. This leads to different
eventual classifications by our prediction rule. We contend that the ultimate
classification of a patient should not depend on the characteristics of the test
set, but rather solely on the characteristics of the patient himself.
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values under the assumption that any transformation applied to the data is
rank-preserving.
As a concrete example, we focus on the PAM50 signature for breast cancer
subtyping [63] which is used to assign patients with breast cancer to one of five
molecular subtypes: Basal, Luminal A, Luminal B, Her2, Normal. We show
that when the number of patients in the test set changes, the predictions for a
single patient may change dramatically. We also show that variation in patient
populations being predicted upon leads to test set bias. Interestingly, PAM50
can be easily modified into a rank-based signature. We show that predictions
from rank-based PAM50 are comparable to those from standard PAM50, and
that predictions from rank-based PAM50 are invariant to test set bias.
Test set bias is a failure of reproducibility of a genomic signature. In other
words, the same patient, with the same data and classification algorithm, may
be assigned to different clinical groups. A similar failing resulted in the cancel-
lation of clinical trials that used an irreproducible genomic signature to make
chemotherapy decisions [50]. The implications of a patient’s classification chang-
ing due to test set bias may be important clinically, financially, and legally. In
the example of PAM50, a patient’s classification could affect a treatment or
therapy decision. In other cases, an estimation of the patient’s probability of
survival may be too optimistic or pessimistic. The fundamental issue is that
the patient’s predicted quantity should be fully determined by the patient’s ge-




Study population and data
We collected and curated gene expression microarray data representing 28 inde-
pendent studies [37]. These datasets spanned 15 different proprietary platform
types and a variety of platform versions and included a range of commercial
and private manufacturers, spanning Affymetrix, Illumina, and Agilent as well
as custom arrays. The data were collected from the Gene Expression Omnibus
(GEO) [9], ArrayExpress [64], The University of North Carolina at Chapel Hill
database (UNCDB), Stanford Microarray Database (SMD), and Journal and
Authors’ websites. Metadata were manually curated as previously described
[37]. Experiments ranged from 43 to 1,992 patients, with a median of 131 pa-
tients and a total of 6,297 patients. (Table 2.1).
PAM model fitting
Prediction Analysis of Microarrays (PAM) [82] is a commonly used supervised
learning approach for building prediction models using gene expression data
from microarrays. We employed the pamr package [40] to fit a PAM model using
R. Briefly, pamr takes class labels and microarray data and calculates an average
gene expression profile, or centroid, for each class. It then shrinks the centroid to
eliminate genes that do not contribute to explaining variability between classes.
We then cross-validate to find an appropriate shrinkage threshold to maximize
predictive accuracy of our model. We use this threshold to determine how many




Age (years) 57.29 (13.42)
RFS (years) 7.22 (4.86)




























Table 2.1: Baseline characteristics of curated dataset Abbreviations:
ER - estrogen receptor status; Her2 - human epidermal growth factor receptor
2 status; Node - whether or not cancer has spread to lymph nodes; PGR -
progesterone receptor status; RFS - recurrence-free survival time. Age, RFS,
Tumor Size are given as means with standard deviations. 1due to the ambiguity
of grade 2, we chose to build all prediction models for grades 1 and 3 only.
2subtypes as predicted by PAM50.
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Normalization procedure
Normalization is accomplished through quantile rescaling as implemented in
the genefu package [39]. This scales each gene expression value x using specific
quantiles from the expression data. First, a quantile q is chosen. Through
examination of many microarray datasets, q = 0.05 was found to be robust. The
expression values corresponding to the desired quantiles q1 = x q
2
and q2 = x1− q
2
are defined, and the scaled value x′ =
x− q1
q2 − q1
is calculated. In contrast to
scaling by the maximum and minimum value, this approach is more robust to
extreme outlying gene expression values.
This normalization procedure is applied internally when the intrinsic.cluster.predict
function from the genefu package is used and the model’s standardization (“std”)
parameter is set to “robust”. For example, we can make PAM50 predictions
using pre-packaged models in genefu called pam50 or pam50.robust. The gene
centroid information is the same in both cases, but pam50 has std = “none”
and pam50.robust has std = “robust”. This means that if we apply intrin-
sic.cluster.predict with pam50, the test data will not be normalized in any way,
but if we use pam50.robust the quantile rescaling procedure described above
will be applied.
Estimating test set bias
We used two approaches to estimate test set bias. When considering the PAM50
predictor, we simply applied the pre-defined prediction model from the genefu
package ([39]) to make predictions on our data.
To train a PAM model, we used 10-fold cross-validation. We create a test
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set that is approximately 10% of the total data and use the remaining 90% to
train the model. We use the internal cross-validation functions provided in the
pamr package [40] to produce a shrinkage threshold and determine the number
of genes necessary to make predictions. We then apply this predictor both in the
test set, which comes from the same platform, and on other microarray datasets
that used different platforms. This process is repeated within each of the cross-
validation folds to get average prediction accuracies and standard deviations.
When predicting tumor grade (1-3 with increasing severity), we restricted to
patients graded 1 or 3 as grade 2 is considered to be ambiguous.
2.4 Results
Normalization makes patient predictions depend on other
patients’ data
Consider the PAM50 signature [63]. The class assignment for a new patient is
made by calculating a measure of closeness between the new patient and the
average patient profile in each possible class, then choosing the class that was
closest to the sample. For example, PAM50 consists of 50 genes and predicts
five classes, so each class centroid is a profile of the average expression of each
of the 50 genes within that class. The authors used correlation as a measure
of closeness for a given sample to each class centroid - that is, correlation is
calculated between the 50 genes in the patient sample and the 50 genes in each
class centroid. This is the step that necessitates suitable rescaling of the test
data before predictions are made.
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We considered two scenarios which illustrate how PAM50 can produce vary-
ing subtype predictions for a particular patient when the data for other pa-
tients used in normalization varies. We used data from GSE7390 (n=198), an
experiment conducted using the Affymetrix hgu133plus2 microarray. In each
experiment, we normalized the gene expression measurements in the test set to
fall between 0 and 1.
First we created predictions where we normalized all patients together. Then
we calculated predictions for the same patients when normalized in smaller
groups (n=2,10,20,40,80,100,120) and measured the agreement between the pre-
dictions for the exact same patient when normalized with all patients versus a
smaller subset of patients. When normalized in small batches, the predictions
for the same patient changed compared to the case where all patients were
normalized together Figure 2.2A.
Next we predicted on patient populations that varied in the distribution of
ER (Estrogen Receptor) status, which is an important factor in breast cancer
prognosis and treatment. Again we applied the PAM50 predictor to the entire
test set. Then we created subsets of the entire test set with differing percentages
of ER-negative patients and applied the predictor to each subset. When the
percentage of ER-negative patients in the subset matched the percentage in the
entire test set, patient subtypes best agreed with the original predictions on the
entire test set. However, when the ER status of the other patients in the test set




Grade 1 3 1 3 1 3
Train Norm. Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d.
Affy Scaled 0.92 0.13 0.67 0.17 0.72 0.05 0.63 0.02 0.95 0.01 0.57 0.02
Unscaled 0.92 0.13 0.65 0.16 0.79 0.02 0.59 0.01 0.97 0.01 0.51 0.03
Agilent Scaled 0.93 0.02 0.59 0.04 0.72 0.32 0.56 0.05 0.96 0.01 0.41 0.03
Unscaled 0.94 0.02 0.55 0.04 0.72 0.32 0.65 0.09 0.97 0.01 0.34 0.05
Illumina Scaled 0.87 0.00 0.75 0.04 0.75 0.02 0.64 0.01 0.92 0.06 0.65 0.05
Unscaled 0.79 0.03 0.87 0.02 0.83 0.02 0.58 0.01 0.84 0.08 0.71 0.06
Table 2.2: Average accuracy of scaled and unscaled predictions over
different training and testing sets We trained a PAM model to predict tu-
mor grade (either grade 1 or 3) using 10-fold cross-validation on one Affymetrix
(GSE7390), Agilent (ISDB10845), and Illumina (ISDB10278) dataset each. The
left column presents upon which platform each model was trained, and the top
row presents upon which platform each trained model was applied to make
predictions. To get average accuracy and standard deviations for a particular
platform, we use the model generated under each fold of the cross-validation
to make predictions on the remaining test set of the same platform as well as
the two other platforms. We applied this model after normalizing (“scaled”)
the data and after leaving it unnormalized (“unscaled”). We find that the ac-
curacies for predicting grade were similar whether the data were normalized or
unnormalized.
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Using gene ranks with unnormalized data produces com-
parable accuracy
When PAM50 was proposed, the authors chose to calculate similarity based on
Spearman correlation ([63]). Spearman correlation finds the correlation between
the ranks of the two sets of gene expression measurements rather than correla-
tion between the actual values. We hypothesized that this rank-based prediction
would be immune to some changes of scale across platforms and other platform-
specific artifacts. With traditional signatures, these are precisely the reasons
why normalization is necessary. To examine this preliminarily, we re-ran the
process from the previoius section but simply did not normalize the data and
relied on the internal rank-based correlation calculation. We recreated Fig-
ures 2.2A & B when the data were “unscaled”. These appear as Appendix
Figure 7.1, and they show that the predictions remain constant as sample size
and ER status vary when the data are unnormalized and a rank-based metric
is employed.
To further evaluate this hypothesis we used the previously proposed PAM
signature-building procedure [82] to build a genomic signature to predict tumor
grade (a clinical quantity indicating severity) using three datasets measured
on different platforms: GSE7390 (Affymetrix; n=198), ISDB10845 (Agilent;
n=337), and ISDB10278 (Illumina; n=1,992). We used 10-fold cross-validation
to train a model on a particular dataset, made predictions on the testing portion
of that dataset, and applied the trained model to the two remaining datasets
which represent two different platforms. We averaged over the ten folds in each
case to obtain mean accuracy and standard deviation.
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To make predictions, we used Spearman correlation to mimic how the PAM50
signature is used [63]. We predicted new patient samples using our PAM sig-
nature for grade both with and without normalization. The same set of genes
and prediction algorithm are used in both cases - the only difference is that in
the former we normalize the test set patient data, and in the latter we leave it
unnormalized. We observed that the normalized and un-normalized predictors
performed similarly across platforms Table 2.2.
Within-platform (Affy-Affy, Agilent-Agilent, Illumina-Illumina inTable 2.2),
there is no appreciable difference in the average accuracy of predictions when
the test data are normalized or unnormalized. For Affy, the grade 1 and 3 av-
erage accuracies when the data are normalized are 0.92 (0.13) and 0.67 (0.17),
respectively, as compared to 0.92 (0.13) and 0.65 (0.16) when the data are un-
normalized. For Agilent, the relevant figures are 0.72 (0.32); 0.56 (0.05) for
normalized vs. 0.72 (0.32); 0.65 (0.09) for unnormalized, and for Illumina 0.92
(0.06); 0.65 (0.05) vs. 0.84 (0.08); 0.71 (0.06). In all cases, the ranges of the
unnormalized average accuracies substantially overlap those of the normalized
average accuracies. Results across platforms (the off-diagonal table entries) tell
a similar story. It is the case that if the scaled predictor performs better on
grade 1 than the unscaled, then the opposite will be true for grade 3 (see, for
example, the Affy-Agilent result). This is due to the fact that patients can be
classified as either grade 1 or 3, so if the unscaled version predicts more grade 3
than grade 1, the change in the respective accuracies will be proportional. This
analysis suggests that using the PAM predictor for grade with Spearman corre-
lation for making classifications without normalizing the test set data produces
similar predictive accuracy to when the test data are normalized.
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2.5 Discussion
We found that breast cancer tumor subtype predictions varied for the same
patient when the data for that patient were processed using differing numbers
of patient sets and patient sets had varying distributions of key characteristics
(ER status). This is undesirable behavior for a prediction algorithm, as the same
patient should always be assigned the same prediction assuming their genomic
data do not change. The fact that sample size affects normalized data values is
unsurprising, but the fact that classifications varied by how many patients were
ER- in the test set speaks to the generalizibility of an algorithm. Ideally, the test
set should be “similar” in composition to the dataset upon which a classification
algorithm was trained. The result in Figure 2.2B is undoubtedly related to
the fact that ER+ patients are different in terms of gene expression from ER-
patients, but we see that even slight perturbations in the ER composition of
the subpopulation can affect patient classifications. This raises the question of
how similar the test set needs to be to the training data for classifications to be
trusted when the test data are normalized.
The PAM50 signature uses Spearman correlation to assess distances when
making predictions, so we leveraged this by comparing how a PAM signature
using Spearman correlation predicts tumor grade outcomes with and without
normalization. We found the results to be comparable, but the unnormalized
approach guarantees the same prediction for the same patient every time. A
gene signature that employs rank-based features or makes other rank-based
calculations is one robust approach to avoiding test set bias. Although all gene
signature classifiers do not necessarily have a completely rank-based mode as
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PAM50 does, the broader implication of this result is that one may endeavour
to build predictors that operate on the ranks of data only, thereby bypassing
the need for any normalization step when predicting on a test set.
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Chapter 3
A Standardized Approach to
Building Gene Signatures with
Rank-Based Features
3.1 Abstract
The development of a gene signature often involves complicated and irrepro-
ducible data modeling and prediction schemes. Here, we introduce a novel gene
signature building algorithm and the Templated Deterministic Statistical Ma-
chines (tdsm) R package. We first describe the statistical underpinnings of an
approach that relies on rank-based genomic features with the intention of creat-
ing small, interpretable predictive models. We then demonstrate this approach
and compose an R Markdown template of the data analysis. We use this tem-
plate to motivate the use of the tdsm package, which promotes transparency
and documentation of a statistical analysis by limiting user-driven adjustments.
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3.2 Introduction
Apart from a handful of success stories [84, 83, 63] translation of gene signatures
from research to clinic has been slower than desired. One primary cause is
difficutly with the interpretation and reliability of the underlying predictive
model that maps gene expression measurements to an outcome prediction [24].
Another major issue is the lack of reproducibilty plaguing many facets of the
signature-building process. We have previously shown that normalization and
data pre-processing steps may lead to undesired biases in predictions made
by gene signatures [65], which represents an issue with the reproducibility of
predictions from a particular gene signature model. Others have described issues
with the process of model-building, which propegate in insufficient validation
[86], technical oversight [5, 46], and can lead to retraction of seemingly promising
genomic predictors [75].
To address reproducibility of predictions, we describe a modeling approach
predicated on simple decision trees [81] which use rank-based Top-Scoring Pairs
(TSPs) [32] as predictive features. These features are not prone to the normal-
ization and pre-processing issues that may be encountered when dealing with
raw gene expression values. We also summarize a novel feature selection scheme
that produces relevant and informative gene pairs under very few parametric
assumptions.
These methods are bundled into a new R package, tdsm (https://github.com/
prpatil/tdsm), which uses R Markdown to produce a standard HTML report
that describes precisely how the resulting decision tree model is built. Having
this report generated every time a gene signature is built will allay some of the
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questions surrounding the reproducibility of the model-building process. Writ-
ten description of each step and the required code are made available within the
document, which can be easily shared and examined. We use this templated
analysis to build an alternative to the MammaPrint signature which uses fewer
genes and a more interpretable model to make predictions of risk of recurrence
in breast cancer.
Finally, we describe the structure of the tdsm package as it pertains to
supporting multiple such templated analyses. We restrict user input to the
analysis of choice to only the required data. As a result, users have no control
over parameters, which are set by default as part of the analysis template. The
user may wish to duplicate a given template and edit parameter choices before
running the analysis. For this contingency, we provide duplicate template
and diff template, which allow the user to document a comparison between
the edited template and the original. The user is therefore informed of how
their changes to the template propagated into changes in their results.
3.3 Methods
Suppose we have a training dataset consisting of n patients and m genes whose
expression has been characterized. We also have some outcome vector Y ∈
{0, 1} of length n. Similarly, we have a validation dataset consisting of p patients
and m genes, with outcome vector W ∈ {0, 1} of length p. We wish to extract
some subset g ∈ m and define a mapping f : g 7→ {0, 1}.
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3.3.1 Top-Scoring Pairs
The base feature used for prediction is the Top-Scoring Pair (TSP), first sug-
gested by Geman et. al. [32]. For individual i and for two gene expression
values, gij, gik ∈ m, we may consider the indicator of the expression of the first
gene being less than the expression of the second, zijk = I(gij < gik). In our
setting, the TSP would be the pair of genes that maximizes |P (gij < gik|yi =
0) − P (gij < gik|yi = 1)|. In a regression setting, fitting the regression model
E[zijk|yi] = β0 + β1yi and choosing maxjk|β1| yields the TSP.
Ideally, we would be able to examine all pairwise comparisons of m genes to
choose the TSP, but aside from the computational difficulty, we would find that
most gene pairs would not make good predictive features; i.e., most pairs are
likely to find gij < gik holds for all yi, hence class differentiation is not possible.
Instead, we propose some feature selection approaches that allow us to consider
useful pairs in a tractable manner.
3.3.2 Feature Selection - Empirical Controls
To find G we employ a two-step feature selection algorithm. The first step, em-
pirical control feature selection, is a filtering step that does not use the outcome
vector Y to pare down the list of candidate gene pairs. As described above, if
we consider all pairwise comparisons of m genes most are likely to be unsuitable
for differentiating classes, i.e. the vector Zjk = I(gij < gik) ∀i will have zeros
or ones in large proportion. Instead, under empirical controls, we search for a
specific type of gene pair that has a better chance of “flipping” between the two
classes. The pair we desire is one where gj has fairly constant gene expression
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across all individuals (the empirical control), while gk has high variance in ex-
pression across all individuals. Figure 3.1 displays an example pair of genes
that exhibit this relationship.
The procedure to find these candidate pairs is as follows:
1. Sort m genes by their average expression and separate into groups by Q
quantiles.
2. Within each quantile grouping, compute and sort by variance and identify
the h highest- and lowest-varying genes (2h total genes).
3. Create all possible pairs between the h highest- and h lowest-varying genes.
Figure 3.2 displays the advantage of choosing pairs via the empirical con-
trol method. We computed the proportion of ones in the vector Zjk for 6400
randomly selected gene pairs, and did the same for 6400 gene pairs selected
via empirical controls. The histogram for the randomly selected pairs has large
atoms at zero and one, suggesting that most pairs of genes consist of one gene
whose relative expression dominates the other. The histogram for the pairs
chosen via empirical controls has a more normal shape. These pairs would be
better candidates to associate with an outcome as there is a chance they will
differentiate a class due to more consistent “flipping” behavior.
3.3.3 Feature Selection - Conditional Pair Choice
Once we have a candidate set of genes C derived from the empirical control
feature selection procedure, we wish to identify any pairs that might be predic-
tive of the outcome. We would additionally like to select subsequent pairs that
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Figure 3.1: Pair of empirical control genes exhibiting “flipping” po-
tential. The raw gene expression values (y-axis) for two genes are plotted for
each patient (x-axis). In this case, RP11 (in orange) is the empirical control,
low-variancel gene, while USP7 (in blue) is a high-variance gene from within the
same quantile as RP11. This pair possesses greater potential for differentiating
classes since the relationship between the expression of the two genes is not
constant across all patients.
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provide additional information about the outcome above the already-selected
pairs. To accomplish this, we leverage the fact that the test statistic for β̂1
from the regression E[Y |X] = βX is equal to the test statistic for γ̂1 from the
regression E[X|Y ] = ΓY . A proof of this property is provided in Appendix
B.
Given this property, our conditional pair selection procedure is as follows:
1. Find the pair (j, k) that maximizes the absolute test statistic for β̂1 from
the regression E[Zjk|Y ] = βY
2. Move the vector Zjk to the right-hand side, and find the next pair (r, s)
that maximizes the absolute test statistic for γ̂1 from the regression E[Zrs|Y, Zjk] =





3. Repeat step 2 until the desired number of pairs have been found.
By flipping the regression, we need only change the right-hand side of the
equation once to include the TSP chosen in the previous step. This allows for
faster application of the simultaneous regression equations for all j, k at each
iteration of the procedure. This process produces the set G of gene pairs that
will be used in a decision tree for the prediction of Y . The key attribute of
selecting features in this manner is that once Zjk is chosen and added to the
right-hand side, the next chosen pair, Zrs, represents the maximum absolute
test statistic for yi conditional on the information provided by Zjk.
3.3.4 Decision tree modeling
We use the rpart [81] package in R to build a decision tree using the pairs
chosen through the feature selection steps described previously. We wrap a layer
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of cross-validation around the entire procedure described thus far: before the
empirical control step, we set up five-fold cross-validation and iterate building
the tree on four-fifths of the data and predicting on the held-out one-fifth. We
use cross-validation to estimate out-of-sample accuracy of the final tree model,
which is built using the same procedure but using the whole data.
If the user has provided a validation dataset, then the entire training set
is put through the procedure described above. If a validation dataset has not
been provided, then the full training dataset is split into training and testing
subsets at the outset, and the testing subset is used as a validation dataset. As
a summary, we report the out-of-sample accuracy as estimated through cross-
validation, the predictive accuracy of the model on the validation dataset, and
use the pROC [71] R package to display ROC curves for both the training and
validation data as a means of comparison.
3.3.5 Standardized Reporting and tdsm Package
We use the rmarkdown [10], knitr [90], and knitrBootstrap [41] packages to
render an HTML report that contains code chunks as well as descriptions of the
modeling process. An excerpt from an example report is shown in Figure 3.3.
The user may only provide input data to this report. Parameter choices for
the number of pairs in a model or the number of empirical control pairs are
fixed within the report. We have provided additional utilities should the user
desire to alter these parameters. The goals of developing the tdsm package in
this manner are to (1) be transparent about the analysis process; (2) should
the user make changes to the analysis process, be transparent about what those
changes are and how they affected results.
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due to their changes. We have also provided for file differentiation (the purple
path). After the user has duplicated and edited the template, they can use the
diff template function to produce an HTML rendering of a diff command
(via the diffr package [60], which uses the codediff.js Javascript library).
Within this file, line differences between the original and edited templates are
highlighted and documented. We also allow the user to share this HTML diff
rendering online as an anonymous Github Gist with the submit diff command.
Our eventual intention is to collect the various changes made by different users
to a particular template and determine if the default template ought to be
changed to reflect common usage.
3.4 Discussion
As a proof-of-concept, we build our own gene signature for risk of breast cancer
recurrence using the original MammaPrint training and validation datasets [54].
We provide the ROC curve excerpted from the full report and mark where
the sensitivity and specificity of the actual MammaPrint test would fall for
comparison in Figure 3.5. The model we developed through this procedure
only uses three pairs of genes (six genes total), as compared to seventy genes used
by the MammaPrint model. Both the TSP-based model and the MammaPrint
model possess relatively high sensitivity and low specificity depending on the
choice of a desired threshold. From the ROC curve, we see that both perform
comparably on the validation data.
Examining the decision tree in Figure 3.6, we are more easily able to in-
terpret how each gene pair contributes to the eventual class assignment for a
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Figure 3.4: Schematic workflow of tdsm package. This schematic illus-
trates the different paths a user can take when using the tdsm package. In blue
is the default path, where the user supplies input data to a default template
and views the resulting HTML report. In orange is the alternative path, where
the user chooses to edit a default template and run their input data through
the edited template as opposed to the default. In this case, we recommend the
addition of the purple path, where an edited template is differentiated against
the default and the diff is saved to a separate HTML file. The user has the
option to subsequently upload the saved diff as an anonymous Github Gist so





We have described here one approach to gene signature building that avoids
issues in reproducibility, both in the predictions of the model and in the model-
building process. For the former, we introduce decision trees that use Top-
Scoring Pairs. These are small, interpretable models that do not require data
pre-processing or normalization prior to application as they operate on relative
gene expression. We demonstrated the viability of this modeling procedure by
recreating a simplified version of the MammaPrint risk predictor which com-
pared favorably in sensitivity and specificity to the original.
For the latter, we have described the tdsm R package which contains the
TSP regression procedure as its first templated analysis. Our intention with
this package is to make an analysis process fully transparent and documented.
By restricting user input solely to data, we produce standard reports that can
be easily compared with one another. We also provide utilities in the case that
the user wishes to tune the analysis to their liking. We encourage the user
to differentiate their edited analysis template against the original so that the
differences are documented and the resulting differences in analysis results are
explicable. any normalization step when predicting on a test set.
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Chapter 4
Genomic and Clinical Predictors
for Improving Estimator
Precision in Randomized Trials
of Breast Cancer Treatments
4.1 Abstract
Background: The hope that genomic biomarkers would dramatically and im-
mediately improve care for common, complex diseases has been tempered by
slow progress in their translation beyond bioinformatics. We propose a novel
use of genomic information where the goal is to improve estimator precision
in a randomized trial. We analyze the potential precision gains from the pop-
ular MammaPrint genomic signature and clinical variables in simulations of
randomized trials analyzed using covariate adjustment.
Methods: We apply an estimator for the average treatment effect in the trial
that adjusts for prognostic baseline variables to improve precision [21]. This
precision gain can be translated directly into sample size reduction and cor-
responding cost savings. We conduct simulation studies based on resampling
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genomic and clinical data of breast cancer patients from four publicly available
observational studies.
Results: Separate simulation studies were conducted based on each of the four
data sets, with sample sizes ranging from 115 to 307. Adjusting only for clinical
variables provided gains of -1%, 5%, 6%, 17%, compared to the unadjusted
estimator. Adjusting only for the MammaPrint genomic signature provided
gains of 2%, 4%, 4%, 5%. Simultaneously adjusting for clinical variables and the
genomic signature provided gains of 2%, 6%, 7%, 16%. The differences between
precision gains from adjusting for genomic plus clinical variables, versus only
clinical variables, were -1%, 0%, 1%, 3%.
Conclusions: Adjusting only for clinical variables led to substantial precision
gains (at least 5%) in three of the four data sets, with a 1% precision loss in
the remaining data set. These gains were unchanged or increased when sample
sizes were doubled in our simulations. The precision gains due to incorporating
genomic information, beyond the gains from adjusting for clinical variables, were
not substantial.
Keywords: adjustment, genomics, precision, translation
4.2 Introduction
The announcement of the Precision Medicine Initiative [23] stated that “Pre-
cision medicine’s more individualized, molecular approach to cancer will enrich
and modify, but not replace, the successful staples of oncology – prevention, di-
agnostics, some screening methods, and effective treatments – while providing
a strong framework for accelerating the adoption of precision medicine in other
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spheres.” In the realm of genomic biomarker development, this mandate puts
an explicit focus on “enrichment”, i.e. how much additional information a new
marker can provide to supplement the standard course of care. The uncertain
value of genomic measurements for improving clinical practice has been a criti-
cal roadblock in the translation of genomic markers to the clinic [16], in addition
to problems with reproducibility [6], interpretability [49], and cost [3]. A small
number of laboratory tests based on genomic signatures have been approved for
clinical use. Tests such as MammaPrint [83], Oncotype DX [61], and Prosigna
[63] rely on measurement of expression for a set of genes that are associated
with differential survival and severity of breast cancer cases.
It is difficult to evaluate the clinical value that these genomic signatures add
beyond standard clinical factors measured for all breast cancer patients, such
as age, estrogen receptor status, tumor size, and tumor grade. It is also known
that tests based on genomic signatures are not part of the standard of care in
many cases [25, 16]. Ongoing clinical trials are being performed to ascertain
the value of some of these signatures to make adaptive treatment decisions [8].
We propose to evaluate the use of genomic signatures in a different setting by
considering the prognostic value added from adjusting for a genomic signature
in a randomized clinical trial of a new treatment versus control.
In a randomized trial the primary analysis typically involves estimating the
average treatment effect. Adjusting for baseline variables that are prognostic for
the outcome can lead to improved precision in estimating the average treatment
effect at large sample sizes (i.e., asymptotically as sample size grows). [91]
showed that for continuous outcomes and a linear model with main terms, the
analysis of covariance (ANCOVA) estimator is guaranteed to be consistent and
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as or more precise than the standard unadjusted estimator, even if the linear
model is not correctly specified, i.e., the true distribution of the outcome given
baseline covariates may be much more complex than the linear model used, and
still the guarantee holds.
More recently, estimators with the same desirable property as the ANCOVA
procedure have been extended to binary and count outcomes; see [18, 80, 73]
and [36]. [21] provide a review of these recent estimators, which are designed to
estimate an average treatment effect in the general setting of an observational
study, where the probability of being assigned to treatment is not randomized
and must be learned from the data. These estimators may also be applied to
randomized trials, where their guarantees on improved precision require fewer
assumptions than in an observational study since in a randomized trial the
assignment probability is known (and set by design).
The above estimators all have the aforementioned consistency and precision
guarantee. One difference among them is that the estimators of [91, 80]; and [21]
do not require solving a non-convex (and therefore computationally challenging)
optimization problem; however, the benefit of solving such a problem, as done
by the estimators of [18, 73] and [36], is that they have potential for further
precision gains, so there is a computation versus precision tradeoff.
The precision gains provided by adjusting for baseline variables depend on
how correlated the baseline variables are with the outcome and the degree of
chance imbalance in the baseline variables across the treatment groups. To the
best of our knowledge, the value of such adjustment has not yet been assessed
using simulations based on resampling from breast cancer patient data sets, as
we do here. We resample in a way that preserves correlations between baseline
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variables and the outcome in order to give a realistic assessment (as best as we
can using simulations and our data sets) of the magnitude of precision gains
likely to be observed in practice.
We aim to determine the prognostic value of clinical and/or genomic vari-
ables measured at baseline (pre-randomization). Of particular interest is the
additional gain from adjusting for the genomic signature beyond that obtained
by adjusting for standard clinical baseline variables. Our definition of preci-
sion gain in this setting equals the percent sample size reduction from using
the adjusted estimator compared to the unadjusted estimator in order to attain
the same power, asymptotically. Although perhaps not as groundbreaking of a
result as once hoped, this approach represents a realistic attempt to assess the
value of the information provided by a genomic signature.
4.3 Methods
4.3.1 Data
Microarray data used to validate the MammaPrint model [17] were gathered as
described in the appendix of [55]. The MammaPrint validation data set consists
of 307 breast cancer patients. Table 4.1 summarizes the key clinical factors
recorded for these patients as well as their MammaPrint risk prediction, which
is a binary classification based on the risk score calculated by the MammaPrint
model [83]. We dropped 11 patients whose estrogen receptor (ER) status or
tumor grade were unknown and conducted our analysis using the 296 remaining
patients.





















Table 4.1: MammaPrint validation data set. ER - estrogen receptor sta-
tus, Grade - tumor severity grading (3 is most severe), Five-Year Recurrence -
whether or not cancer has reappeared after five years, MammaPrint risk pre-
diction - high or low risk for cancer recurrence. Age and Tumor Size are given
as means with standard deviations in parentheses.
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sets described in the Supplementary Material (Appendix C). These are called
GSE19615, GSE11121, GSE7390, with sample sizes 115, 200, 198, respectively.
4.3.2 Statistical Method to Adjust for Baseline Covari-
ates
We define the average treatment effect to be the difference between the pop-
ulation mean of the primary outcome under assignment to treatment and the
population mean under assignment to control. The term “covariate adjustment”
means that information from baseline variables is used to improve the precision
in estimating the average treatment effect. This is done by adjusting for chance
imbalances in baseline variables between treatment and control arms. Since
our focus is improved precision for estimating the average treatment effect, we
do not consider effects within subgroups; investigating the latter is an area for
future research.
Increased precision for estimation of the average treatment effect can lead
to a trial with fewer participants and shorter duration, compared to a trial with
the same power that uses a less precise estimator. This is because the sample
size for a trial is typically selected in order to achieve a desired power, e.g.,
80% or 90%, at an alternative (e.g., the minimum, clinically meaningful effect
size); using a more precise estimator leads to a smaller required sample size
to achieve the power goal. More precise estimators can be used to reduce the
sample size even when the average treatment effect is zero, which is the setting
of our simulation study. This can be achieved by prespecifying the sample size as
that which achieves a desired power at a given alternative, taking into account
the percent variance reduction from using the adjusted estimator compared to
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the unadjusted estimator. A more flexible approach is to use information based
monitoring, where the trial runs until a preplanned information level has accrued
(see, e.g., [44]). Information with respect to a given estimator, defined as the
reciprocal of its variance, accrues faster for estimators with greater precision,
leading to smaller sample sizes.
We assume each participant in the trial contributes a data vector D =
(W,A, Y ), where W = (W1, . . . ,Wj) is a vector of covariates measured at base-
line, A is an indicator of study arm (0 = control, 1 = treatment), and Y is a
binary outcome of interest which in our case is the indicator of cancer recurrence
within 5 years from baseline. We assume the trial data consist of n independent,
identically distributed participant data vectors {Di}ni=1 drawn from unknown
joint distribution P on (W,A, Y ). We assume a nonparametric model except
that W and A are independent by randomization (called the randomization
assumption), and we assume the regularity conditions in [21, Section 3.2].
The goal is to estimate the average treatment effect defined as the difference
between 5 year survival probabilities comparing treatment versus control, i.e.,
ψ = E[Y |A = 1]− E[Y |A = 0] = P (Y = 1|A = 1)− P (Y = 1|A = 0). (4.1)
Another possible treatment effect, which we do not consider, is the hazard ratio
under a proportional hazards model. This would have the advantage that the
recurrence time (rather than only the indicator Y of recurrence by 5 years) is
fully used; however, a disadvantage is that inferences depend on the proportional
hazards assumption being correct, and these inferences would typically be biased
(even at large sample sizes) if that assumption fails to hold.
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This estimator is consistent (i.e., converges in probability to the population
average treatment effect ψ) but ignores the baseline variables W . If W is prog-
nostic for Y then it is possible to improve precision by appropriately adjusting
for W . Throughout, we do not assume that W contains information about
treatment effect heterogeneity, i.e., who benefits more or less from treatment;
we only use W as prognostic variables that may explain some of the variation
in Y . This variation could be unrelated to treatment.
To leverage the information in W , we apply the enhanced efficiency, doubly-
robust estimator of [21, Section 4.2], which is a special case of the class of
estimators from [73] that is slightly modified for use in the randomized trial
context. We denote this estimator by ψ̂adj. Software to compute this estimator
is given in R and SAS by [21]. The R code we used is available at the link in
Section 2.5.
The estimator ψ̂adj uses parametric working models for the mean of the
outcome given baseline variables and study arm. We call these working models
since we do not assume they are correctly specified. The true data generating
distribution may differ arbitrarily from the functional form of the model.
Computation of ψ̂adj is accomplished via the following steps:
1. Let α = (α0, . . . , αj)
T . Fit the following propensity score working model
for P (A = 1|W ): g(W,α) = logit−1 (α0 + α1W1 + . . .+ αjWj) via maxi-
mum likelihood estimation and denote the estimator of α by α̂ = (α̂0, . . . , α̂j)
T .
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. Fit the above model




ing only participants with A = 1 to obtain estimated coefficients β̂(1) =
(β̂
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0 , . . . , β̂
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(1)), where the sum is taken over all participants. The
estimator µ̂0 for E[Y |A = 0] is obtained analogously by setting a = 0, re-





1− g(W, α̂) above.
3. Define the new covariate µa(W ) = Q
(a)(W, β̂(a))− µ̂a for each a ∈ {0, 1},
which uses µ̂a, β̂
(a) as estimated in step 2. Fit the following augmented
propensity score model for P (A = 1|W ): gaug(W,α, γ) = logit−1(α0 +
α1W1 + . . . + αjWj + γ0µ0(W ) + γ1µ1(W )) using maximum likelihood
estimation to obtain estimated coefficients α̃ and γ̃ = (γ̃0, γ̃1).
4. Recompute step 2 using gaug(W, α̃, γ̃) in place of g(W, α̂) in the weights to
obtain new estimates µ̃1, µ̃0. Define the adjusted estimator of the average
treatment effect as ψ̂adj = µ̃1 − µ̃0.
Throughout, we assume there are no missing data and the vector (Wi, Ai, Yi)
is observed for each participant i. The models g and gaug are correctly specified
as long as each contains an intercept due to the randomization assumption. By
design, each participant is assigned to treatment or control with probability 0.5,
independent of his/her baseline variables, so P (A = 1|W = w) = P (A = 1) =
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0.5 for all values of w. Consider the model
g(W,α) = P (A = 1|W ) = logit−1(α0 + α1W1 + . . .+ αkWk)
Setting α1 . . . αk = 0 and α0 = logit(1/2) yields correct specification of the
model, i.e., the model at these parameter values equals the true distribution
P (A = 1|W ) = P (A = 1) = 1/2. The same holds for gaug. Though the data
generating distribution has A independent of W , in any given realization of the
data there can be imbalances in W across arms due to chance variation.
The models Q(0), Q(1) will typically be misspecified if any of the baseline
variables is continuous valued or has many discrete levels. An important feature
of the estimator ψ̂adj is that it is consistent regardless of whether the parametric
models Q(0), Q(1) are correctly specified; that is, consistency holds even when
the true data generating distribution E(Y |A = a,W ) does not have the form
Q(a)(W,β(a)) for any β. Furthermore, the estimator ψ̂adj is guaranteed to have
asymptotic precision equal to or greater than that of the unadjusted estimator
as proved by [73, 21]. However, depending on the number of baseline covariates
and the sample size, the precision may be worse for the adjusted estimator
compared to the unadjusted estimator; this can happen if the baseline variables
are only weakly (or not at all) prognostic, there are more than a few of them,
and the sample size is relatively small.
It is also possible to use the output of step 2 to construct the simpler es-
timator µ̂1 − µ̂0 of the average treatment effect. This estimator is called the
double-robust weighted least squares estimator (DR-WLS) and is attributed to
Marshall Joffe by [72]. The value of adding steps 3 and 4 is that the resulting
estimator has been proved to be asymptotically as or more precise than the
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unadjusted estimator [73, 21].
4.3.3 Baseline Covariates used for Adjustment
The baseline variables W used in the estimators defined above must be pre-
specified. They can be any functions of measurements made prior to random-
ization. We define four sets of covariates that we will adjust for using the
procedure described in Section 2.2:
• W−ER : {Age, Tumor Size, I(Tumor Grade = 2), I(Tumor Grade = 3)}
• WC : {Age, Tumor Size, I(Tumor Grade = 2), I(Tumor Grade = 3), ER
Status}
• WG: {MammaPrint Risk Category}
• WCG: {Age, Tumor Size, I(Tumor Grade = 2), I(Tumor Grade = 3), ER
Status, MammaPrint Risk Category}
Here, I(Tumor Grade = 2) is an indicator of whether or not the patient’s tumor
is severity grade 2.
With these four sets of covariates, we are able to contrast gains in precision
from different covariate sources. We compare adjusting for WC versus W−ER to
determine how much adding the clinical covariate ER status to other clinical
covariates improves precision. We also compare the prognostic value of the
genomic predictor plus clinical covariates (WCG) versus clinical covariates alone
(WC).
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We consider the clinical covariates above because they reflect quantities that
clinicians may commonly use to evaluate cancer-related risks and courses of ther-
apy. The number of covariates we are adjusting for here exceeds the conservative
approach recommended by [21]. They recommend 2-3 adjustment covariates at
sample sizes such as ours. The potential downside to adjusting for greater num-
bers of covariates is that we risk non-negligible increases in estimator variance
if our covariates turn out to be non-prognostic for the outcome, as shown in
Section 4.4. We chose to include larger numbers of covariates here in order to
compare the added value of MammaPrint above the prognostic value of the full
set of relevant clinical covariates available in our data sets.
4.3.4 Simulations
We conducted a simulation study with the goal of comparing the variance of the
unadjusted and adjusted estimators to determine how much precision we may
gain from adjusting for clinical and genomic covariates. For each of the four
data sets described in Section 4.3.1 and in the supplement, we construct a data
generating distribution that mimics the observed correlation between baseline
variables and outcomes.
To preserve the relationship between outcome and potentially prognostic co-
variates from the original data set, we resample participants with replacement
and create a new sample of the size of our data set (296 for the MammaPrint
validation data) for each simulated trial; we record (W,Y ) for each resampled
participant. This maintains the empirical joint distribution of (W,Y ), preserv-
ing the correlation of these variables. In each simulated trial, the study arm
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assignment A of each participant is a random draw from the Bernoulli dis-
tribution with probability 1/2 of being 0 or 1, independent of (W,Y ). The
population average treatment effect defined in (4.1) corresponding to the above
data generating distribution is therefore ψ = 0.
The reason we do not simply resample patient data vectors (W,A, Y ) with
replacement from a given data set is that the resulting data generating distri-
bution would not have treatment A independent of baseline variables W (as
in a randomized trial). This is because our data sets are from observational
studies, as opposed to randomized trials. Though it would be preferable to use
data from randomized trials, we were not able to obtain data from any such
trials that also recorded the MammaPrint predictor at baseline. Observational
studies still can provide a rough approximation to the magnitude of potential
precision gains from covariate adjustment, since these gains are directly related
to the variance of Y explained by W [21].
For each data generating distribution described above, we construct J =100,000
simulated trial data sets, each of sample size equal to the original data set (ex-
cluding patients with missing data). Using the jth simulated data set, we com-
pute the unadjusted estimator ψ̂juna and the adjusted estimator ψ̂
j
adj using each
of the covariate sets W−ER,WC ,WG,WCG. We then approximate the bias and
variance of each of these estimators based on its values over the 100,000 simu-
lated trials. Since ψ = 0, the bias B of an estimator ψ̂ is E(ψ̂)−ψ = E(ψ̂), which
is approximated by the average of ψ̂ over the 100,000 simulated trials we con-
ducted. We similarly approximate the variance of each estimator. For the un-
adjusted estimator, the approxmiate bias and variance based on our simulation
















respectively. The bias and variance approximations for the adjusted estimator















For conciseness, we refer the these approximations as the bias and variance
of the corresponding estimator, rather than writing “approximate bias” and
“approximate variance”.
We define the (percent) precision gain due to the adjusted estimator in




x 100%. The precision gain equals, asymptotically (as sam-
ple size goes to infinity), the percent reduction in sample size to achieve a desired
power at a local alternative comparing the adjusted versus unadjusted estima-
tor. It equals 1−1/RE, where RE is the asymptotic relative efficiency. Negative
values of Gadj correspond to efficiency losses, which can occur if baseline vari-
ables are only weakly (or not at all) prognostic for the outcome. Asymptotically
(as sample size goes to infinity), Gadj converges to a nonnegative value, which
represents zero or positive precision gain, as proved by [73, 21].
Simulations were conducted via the BatchJobs R package [13], which allows
for an interface between R and a cluster queuing system. We parallelized such
that 1000 simulated data sets were constructed concurrently by each of 100
processors on a Sun Grid Engine (SGE) cluster, which sped up the computation
of our approximations.
We also conducted simulation studies as above except where the sample
size in each simulated trial is double that of the original data set. In all of
our simulation studies, each simulated participant’s data is an independent,
identically distributed draw from a joint distribution P (which depends on the
data set being resampled from) on (W,A, Y ). Therefore, even though we are
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resampling (with replacement) double the sample size n from the original data
set, the effective sample size is 2n (i.e., each estimator’s variance is roughly cut
in half compared to its variance at the original sample size.) To illustrate this
point, consider the analogy of drawing n independent, identically distributed
realizations Y1, . . . , Yn from a Bernoulli distribution with true probability 1/4
of being 1. Though this is equivalent to resampling n times with replacement
from the four person data set {0, 0, 0, 1} (with equal chance of each), each draw
is independent and the effective sample size equals the number of draws n. The
precision gains from adjustment are expected to be similar or slightly greater
than when the original sample sizes are used, since at larger sample sizes there
is less variability in the estimated coefficients β̂(a) in the working model fits
Q(a)(W, β̂(a)) used in ψ̂adj.
4.3.5 Reproducibility




Table 4.2 presents variances for each estimator and the precision gain Gadj,
using different sets of baseline covariates, for the MammaPrint validation data
set and the data sets GSE19615, GSE11121, GSE7390. All precision gains Gadj
are rounded to the nearest percent.
Consider the left half of Table 4.2, which corresponds to simulated trials
having the same sample size as the corresponding data set. Adjusting only for
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Original Sample Size Double Sample Size








W−ER 0.0018 0.0017 4% 0.00089 0.00084 6%
WC 0.0018 0.0017 5% 0.00089 0.00083 6%
WG 0.0018 0.0017 5% 0.00089 0.00084 5%
WCG 0.0018 0.0017 6% 0.00089 0.00082 7%
GSE19615 data set
W−ER 0.0088 0.0078 11% 0.0044 0.0037 14%
WC 0.0088 0.0073 17% 0.0044 0.0035 21%
WG 0.0088 0.0084 4% 0.0044 0.0042 4%
WCG 0.0088 0.0074 16% 0.0044 0.0035 21%
GSE11121 data set
W−ER 0.0036 0.0034 7% 0.0018 0.0016 9%
WC 0.0036 0.0034 6% 0.0018 0.0017 9%
WG 0.0036 0.0036 2% 0.0018 0.0018 2%
WCG 0.0036 0.0034 7% 0.0018 0.0016 9%
GSE7390 data set
W−ER 0.0045 0.0045 -1% 0.0022 0.0022 1%
WC 0.0045 0.0045 -1% 0.0022 0.0022 1%
WG 0.0045 0.0043 4% 0.0022 0.0022 4%
WCG 0.0045 0.0044 2% 0.0022 0.0021 5%
Table 4.2: Precision gains due to adjustment for different sets of
baseline covariates
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clinical variables (WC) provided precision gains Gadj of -1%, 5%, 6%, 17% (from
smallest to largest), compared to the unadjusted estimator, across the four data
sets. Adjusting only for the MammaPrint genomic signature (WG) provided
gains of 2%, 4%, 4%, 5%. Simultaneously adjusting for clinical variables and
the genomic signature (WCG) provided gains of 2%, 6%, 7%, 16%.
Each of the above precision gains Gadj was unchanged or increased when
each simulated trial has double the sample size as the corresponding data set
(right half of Table 4.2). This is to be expected, as described above. For each
estimator, covariate set, and data set, the variance at double the sample size
was approximately half of the corresponding variance at the original sample
size, as expected.
The additional gain due to the genomic predictor is defined as the differ-
ence between the precision gain from WCG versus WC . First, consider the left
half of Table 4.2, where each simulated trial has the same sample size as the
corresponding data set. In simulations based on the MammaPrint validation
data, the genomic predictor provided an additional gain of 1% above using all
clinical factors. In two of the other data sets, the additional gains due to the
MammaPrint predictor were 0% (GSE11121) and 3% (GSE7390). Using a third
such data set, GSE19615, adjusting for the MammaPrint prediction in addition
to the clinical covariates decreased precision by 1% compared to adjustment for
clinical covariates alone. Such losses in precision can occur when adjusting for
a variable that is only weakly prognostic (or not prognostic) for the outcome.
The additional gains due to the genomic predictor were 0%, 0%, 1%, 4% when
sample sizes in the simulations were doubled (right half of Table 4.2).
We also examined the additional gains due to ER status, defined as the
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difference between the precision gains from WC versus W−ER. These values
were -1%, 0%, 1%, 6%, for the four data sets, based on simulations at the
original sample size. Qualitatively, these were similar to the magnitudes of
additional gains due to the genomic predictor.
We conducted additional simulations where we generated baseline covariates
independent of the outcome, in order to determine the magnitude of precision
losses due to adjusting for pure noise. This quantifies the loss that would occur
if one were to prespecify an analysis that adjusts for variables conjectured to
be prognostic, but these variables turn out to be non-prognostic. We generated
100,000 simulated trial data sets as above, except where the data generating dis-
tribution has baseline variables W independent of Y . This was done by resam-
pling W with replacement from its marginal distribution in the MammaPrint
data set, and similarly resampling Y from its marginal distribution. The results
are shown in Table 4.3. As expected, all combinations of covariates produce
zero or negative precision gains, with greater losses when adjusting for larger
covariate sets (due to more degrees of freedom in the working models). The
maximum loss in precision is 3% when using the original sample sizes (left half
of Table 4.3). This is due to the inclusion of greater than the recommended
number of adjustment covariates, as described in Section 2.3. The potential
losses are smaller if the sample size is larger, as shown in the right half of Ta-
ble 4.3 where the maximum loss is 1%. Larger sample sizes tend to decrease
the magnitude of precision losses since asymptotically (as sample size goes to in-
finity), Gadj converges to a nonnegative value, which represents zero or positive
precision gain, as proved by [73, 21]. We present additional simulation results
with W generated independent of Y in the Supplementary Material where we
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Original Sample Size Double Sample Size







W−ER 0.00177 0.00181 -2% 0.00090 0.00091 -1%
WC 0.00177 0.00182 -2% 0.00090 0.00091 -1%
WG 0.00177 0.00178 0% 0.00090 0.00090 0%
WCG 0.00177 0.00183 -3% 0.00090 0.00091 -1%
Table 4.3: Precision gains under data generating distribution
with W and Y independent, based on marginal distributions from
MammaPrint validation data set.
reduce the number of clinical covariates adjusted for, resulting in smaller preci-
sion losses.
The bias approximations Buna and Badj were both quite small, with mag-
nitudes of at most 0.0003 over the four simulation studies. We examined the
distribution of the differences between ψ̂juna and ψ̂
j
adj over the j = 1, . . . , 100, 000
iterations in the simulation using the Mammaprint validation data set; the his-
togram of ψ̂juna − ψ̂jadj appears in Figure 4.1, and analogous histograms for the
other datasets along with a table comparing the distributions of differences
across the four simulation studies are available in the supplement. For the sim-
ulation with the MammaPrint dataset, we saw an average difference of 0.00005
(standard deviation=0.0145). The 2.5% and 97.5% quantiles of ψ̂juna− ψ̂jadj were
[-0.029, 0.029]; this implies that 95% of the differences between the unadjusted
and adjusted estimators had magnitudes smaller than 3%. The correlation of
the two estimators was 0.94.
In general, we expect the difference between the unadjusted and adjusted
treatment effect estimators to be small unless there is substantial chance imbal-
ance between treatment and control arms that is accounted for by the adjusted
estimator. In that case, we would expect the adjusted estimator to be closer to
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Figure 4.1: Histogram of ψ̂juna − ψ̂jadj. The histogram of differences between
the unadjusted and adjusted estimators is approximately normal and is centered
close to the true effect of zero (mean=0.00005, standard deviation=0.0145). The
adjusted estimator is closer than the unadjusted estimator to the true effect
approximately 53% of the time. For this histogram, we considered the adjusted
estimator using all available baseline covariates (clinical + genomic).
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the true effect. In our setting, the adjusted estimator was closer to the true effect
of zero 53% of the time, suggesting a slight improvement over the unadjusted
estimator.
4.5 Supplementary Material
We provide summaries of the data sets GSE19615, GSE11121, and GSE7390.
We also present a table analogous to Table 4.3 except where we reduce the
maximum number of adjustment covariates to three. The result is that precision
losses are smaller when covariates are generated independent of the outcome Y ,
compared to the precision losses in Table 4.3. These materials can be found
in Appendix C.
4.6 Conclusion
Appropriately adjusting for prognostic baseline covariates has potential to im-
prove precision in estimating the average treatment effect in randomized trials.
If baseline factors are collected for patients enrolled in a study, then adjusting
for them can reduce the sample size necessary to obtain a desired precision in
estimation of the average treatment effect and, therefore, the cost to run the
trial.
The precision gains from adjusting for clinical variables were substantial
(5%, 6%, 17%) in simulation studies based on three out of four data sets we
considered; the last data set led to a loss in precision of 1%. These precision
gains slightly increased when sample sizes were doubled, showing that covariate
adjustment can be valuable both at moderate (115 to 307) and larger sample
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sizes, in the context of breast cancer treatment trials.
The additional gains from adjusting for the genomic predictor were quite
small. We consider several possible explanations for this finding. First, our
estimator may not have effectively extracted the additional prognostic informa-
tion in the genomic marker; e.g., it may be that including interactions between
the MammaPrint score and clinical variables, or using a less parametric model
than logistic regression (e.g., splines), would lead to an adjusted estimator with
better precision than we observed. This is difficult to evaluate, since using more
flexible models could lead to overfit; this may be controllable via penalization or
cross-validation, and is an area of future research. Another possible explanation
is that the MammaPrint risk score is too coarse a summary measure of the 70
gene expression levels measured by the MammaPrint assay, for our purpose.
The MammaPrint risk score was not designed for maximizing additional prog-
nostic value beyond what is explained by clinical variables. It may be that a
different function of the 70 gene expression levels would lead to greater precision
gains, but this is beyond the scope of this paper. A third possible reason for
the lackluster additional gains from the genomic predictor is that there may be
little additional prognostic value in the genomic information for the outcome
we considered. The MammaPrint score in the validation set examined here was
89% sensitive to high risk-of-recurrence patients, 42% specific to low risk-of-
recurrence [55], but these measures ignore the variation that can be explained
by clinical variables.
The additional gain due to the genomic predictor was roughly similar to
the additional gain from including ER status over other clinical covariates. ER
status may lack prognostic power if ER positive participants are treated with
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adjuvant tamoxifen [20]. Similarly, it is possible that the MammaPrint score
influenced treatment decisions, which could lead to decreased prognostic value.
A limitation of our approach is that we used data from observational studies,
rather than from randomized trials. If the prognostic value of baseline variables
is similar in a randomized trial setting, then our results may shed light on the
order of magnitude of precision gains that can be achieved from covariate ad-
justment. However, if the prognostic value of baseline variables for the outcome
is systematically different in a randomized trial, then our results would not ap-
ply. Future work involves applying our simulation approach to randomized trial
data sets. Another limitation of our approach is that we ignore censoring due
to loss to follow up. It is possible to incorporate censoring into our estimator,
under a missing at random assumption, but this is an area for future work.
Our focus was on the prognostic value of different variables, that is, the abil-
ity of these variables to explain variation in the outcome (5 year recurrence). In
contrast, the more ambitious goal of personalized medicine is to find predictive
variables, i.e., variables that discriminate between those who are likely to ben-
efit from a specific treatment or not. Being prognostic is not a prerequisite for
being predictive, e.g., as in the case of ER status. However, the MammaPrint
score having little prognostic value beyond the variation explained by clinical
covariates indicates that its utility for covariate adjustment is limited.
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Chapter 5
A Glass Half-Full Interpretation
of Replicability in Psychological
Science
5.1 Abstract
A recent study of the replicability of key psychological findings is a major con-
tribution toward understanding the human side of the scientific process. De-
spite the careful and nuanced analysis reported in the paper, mass, social, and
scientific media adhered to the simple narrative that only 36% of the studies
replicated their original results. Here we show that 77% of the replication ef-
fect sizes reported were within a 95% prediction interval based on the original
effect size. In this light, the results of Reproducibility Project: Psychology can
be viewed as a positive result for the scientific process.
5.2 Introduction
It is natural to hope that when two scientific experiments are conducted in the
same way, they will lead to identical conclusions. This is the intuition behind the
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recent tour-de-force replication of 100 psychological studies by the Open Science
Collaboration, Reproducibility Project: Psychology [22]. At incredible expense
and with painstaking effort, the researchers attempted to replicate the exact
conditions for each experiment, collect the data, and analyze them identically
to the original study.




























In predict ion interval
Below predict ion interval
Above predict ion interval
Figure 5.1: 95% prediction intervals suggest most replication effects
fall in the expected range A plot of original effects on the correlation scale
(x-axis) and replication effects (y-axis). Each vertical line is the 95% prediction
interval based on the original effect size. Replication effects could either be
below (pink), inside (grey), or above (blue) the 95% prediction interval.
The original analysis considered both subjective and quantitative measures
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of whether the results of the original study were replicated in each case. They
compared average effect sizes, compared effect sizes to confidence intervals, and
measured subjective and qualitative assessments of replication. Despite the
measured tone of the manuscript, the resulting mass, social, and scientific me-
dia coverage of the paper fixated on a statement that only 36% of the studies
replicated the original result [66].
Although we may hope that a properly replicated study will provide the
same result as the original, foundational statistical principles suggest that this
may not be the case. The Reproducibility Project: Psychology study coincided
with extensive discussion on what it means for a study to be reproducible and
how to account for different sources of variation when replicating [45]. Stanley
and Spence [78] showed through simulation how sampling and measurement
variation interplay with the size and reliability of an effect to produce wide
distributions of replication effect sizes. These examinations were accompanied
by discussions of adequate study power [56, 58], sample size [29, 74], and how
meta-analysis may address the consequences of inadequate power or sample size
[15]. Anderson and Maxwell [2] furthered these concepts by categorizing the
different goals of replicating a study and recommending appropriate analyses
and equivalence tests specific to each goal. In sum, the sources of variability
that make replicating the result of a particular study so difficult were well-
documented when the Reproducibility Project: Psychology study was underway.
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5.3 Defining and Quantifying Replication Us-
ing P-values
Despite the nuanced understanding of the factors that affect reproducibility, the
publicized 36% figure refers only to the percentage of study pairs that reported
a statistically significant (P < 0.05) result in both the original and replication
studies. The relatively low number of results that were statistically significant
in both studies was the focus of extreme headlines like “Over half of psychology
studies fail reproducibility test.” [7] and played into the prevailing narrative
that science is in crisis [30].
The most widely disseminated report from this paper is based on a mis-
interpretation of reproducibility and replicability. Reproducibility is defined
informally as the ability to recompute data analytic results conditional on an
observed data set and knowledge of the statistical pipeline used to calculate
them [67, 68]. The expectation for a study to be reproducible is that the ex-
act same numbers will be produced from the same code and data every time.
Replicability of a study is the chance that a new experiment targeting the same
scientific question will produce a consistent result [4, 42]. When a study is
replicated, it is not expected that the same numbers will result for a host of
reasons including both natural variability and changes in the sample population,
methods, or analysis techniques [48].
We therefore do not expect to get the same answer even if a perfect repli-
cation is performed. Defining replication as consecutive results with P < 0.05
squares with the intuitive idea that replication studies should arrive at similar
conclusions. So it makes sense that despite the many reported metrics in the
65
original paper, the media has chosen to focus on this number. However, this
definition is flawed since there is variation in both the original study and in the
replication study, as has been much-studied in the psychology community to
date. Even if you performed 10,000 perfect studies and 10,000 perfect replica-
tions of those studies, you would expect the number of times both P-values to
be less than 0.05 to vary.
We conducted a small simulation based on the effect sizes presented in the
original article. In the original study, the authors applied transformations to 73
of the 100 studies whose effects were reported via test statistics other than the
correlation coefficient (e.g. t-statistics, F-statistics). We simulated 10,000 per-
fect replications of these 73 studies based on one degree of freedom tests. Each
of these 10,000 simulations represents a perfect version of the Reproducibility
Project with no errors. In each case, we calculated the percentage of P-values
less than 0.05. The percentage of P-values less than 0.05 ranged from 73% to
91% (1st to 3rd quartile; high: 100%; low: 6%) with a high degree of variability
(Figure 5.2).
5.4 Prediction Intervals
Sampling variation alone may contribute to “un-replicated” results if you define
replication by a P-value cutoff. We instead consider a more direct approach
by asking the question: “What effect would we expect to see in the replica-
tion study once we have seen the original effect?” This expectation depends
on many variables about how the experiments are performed [35]. Here we
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assume the replication experiment is indeed a true replication - a not unreason-
able assumption in light of the effort expended to replicate these experiments
accurately.
One statistical quantity that incorporates what we can reasonably expect
from subsequent samples is the prediction interval. A traditional 95% confidence
interval describes our uncertainty about a population parameter of interest. We
may see an odds ratio reported in a paper as 1.6 [1.2, 2.0]. Here, 1.6 is our best
estimate of the true population odds ratio based on the observed data. The
range [1.2, 2.0] is our 95% confidence interval constructed from this study. If
we were able to observe 100 samples and construct a 95% confidence interval
for each sample, 95 of the 100 would contain the true population odds ratio.
A prediction interval makes an analogous claim about an individual future
observation given what we have already observed. In our context, given the
observed original correlation and some distributional assumptions (described in
detail in the Methods section), we can construct a 95% prediction interval and
state that if we were to replicate the exact same study 100 times, 95 of our
observed replication correlations will fall within the corresponding prediction
interval.
A crucial characteristic of the prediction interval which makes it a suitable
tool for our purposes is that it takes the variability in the observed data as
well as the future data point into account. This is shown explicitly through
calculation in the Methods section, but the basic concept is that constructing
a prediction interval relies on computing a contrast between a summary of the
observed data (such as the mean, X̄) and the theoretical “next” observation,
Xn+1. Then the variance of the distribution of X̄ − Xn+1 will depend on the
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variance of both X̄ and Xn+1, as will the subsequent interval calculated from
that distribution.
5.5 Using Prediction Intervals to Assess Repli-
cation
Assuming the replication is true and using the derived correlations from the
original manuscript, we applied Fisher’s z-transformation [27] to calculate a
pointwise 95% prediction interval for the replication effect size given the original







is the correlation estimate in the original study; norig, nrep are the sample sizes
in the original and replication studies; and z0.975 is the 97.5% quantile of the
normal distribution (Methods). The prediction interval accounts for variation
in both the original study and in the replication study through the sample sizes
incorporated in the expression of the standard error.
We observe that for the 92 studies where a replication correlation effect size
could be calculated, 69 (or 75%) were covered by the 95% prediction interval
based on the original correlation effect size (Figure 5.1). In two cases, the
replication effect was actually larger than the upper bound of the 95% predic-
tion interval. Considering the asymmetric nature of the comparison, one might
consider these effects as having “replicated with effect clear”. We then estimate
that 71/92 (or 77%) of replication effects are in or above the 95% prediction
interval based on the original effect. Some of the effects that changed signs upon
replication still fell within the 95% prediction intervals calculated based on the
original effects. This in unsurprising in light of the relatively modest sample
sizes and effects in both the original and replication studies (Figure 5.3).
68
We note here that of the 69 replication effect sizes that were covered by the
95% prediction interval, two replications showed a slightly negative correlation
(-0.005, -0.034) as compared to a positive correlation in the original study (0.22,
0.31, respectively). In the first study, the original and replication sample sizes
were 110 and 222; in the second study, they were 53 and 72. We would classify
these two studies as “replicated with ambiguous effect” as opposed to “replicated
with effect clear” due to the change in direction of the effect, although both are
very close to zero. All other negative replication effects did not fall into the
95% prediction intervals, and hence were considered “did not replicate”.
We also considered the 73 studies the author’s reported to be based on one
degree of freedom tests. In 51 of these 73 studies (70%), the replication effect was
within the 95% prediction interval. The same two cases where the replication
effect exceeded the 95% prediction interval were in this set leaving us with an
estimate of 53/73 (73%) of these studies had replication effects consistent with
the original effects.
Based on the theory of the prediction interval we expect about 2.5% of the
replication effects to be above and 2.5% of the replication effects to be below
the prediction interval bounds. Since about 23% were below the bounds, this
suggests that not all effects replicate or that there were important sources of
heterogeneity between the studies that were not accounted for. The key message
is that replication data—even for studies that should replicate—is subject to
natural sampling variation in addition to a host of other confounding factors.
It is notable that almost all of the replication study effect sizes were smaller
than the original study effect sizes, whether or not they fell inside the 95% pre-
diction interval. In the original set of 92 studies, of those where the replication
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effect falls within the 95% prediction interval (69 studies), 55/69 (80%) had a
replication effect size that was smaller than the original effect size. This speaks
to the notion that there are likely a host of biases that pervade the original
study, pertaining mostly to the desire of reporting a small effect that is statis-
tically significant [31]. In this sense, our analysis complements the finding of
the Open Science Collaboration while simultaneously providing some additional
perspective on the expectation of replicability.
5.6 Conclusion
We need a new definition for replication that acknowledges variation in both
the original study and in the replication study. Specifically, a study replicates
if the data collected from the replication are drawn from the same distribution
as the data from the original experiment. To definitively evaluate replication
we will need multiple independent replications of the same study. This view
is consistent with the long-standing idea that a claim will only be settled by
a scientific process rather than a single definitive scientific paper. We support
Registered Replication Reports [76] and other such policies that incentivize
researcher contribution to these efforts.
The Reproducibility Project: Psychology study highlights the fact that effects
may be exaggerated and that replicating a study perfectly is challenging. We
were caught off guard by the immediate and strong sentiment that psychology
and other sciences may be in crisis [30]. Our first reaction to Figure 3 from the
original manuscript was pleasant surprise. The fact that many effects fall within
the predicted ranges despite the long interval between original and replication
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study, the complicated nature of some of the experiments, and the differences
in populations and investigators performing the studies is a reason for optimism
about the scientific process. It is also in line with estimates we have previously
made about the rate of false discoveries in the medical literature [43]. While
there is a work to be done, the glass may not be quite as empty as the prevailing
narrative would suggest.
We stress that the approach outlined here of is easily applied when the
result of interest in a study can be summarized by one value upon which we can
ascribe distributional assumptions. In reality, most scientific studies are quite
a bit more complex, dealing in multiple stimuli [87], adaptation over time and
circumstance [12], and complicated data sources [19], just to name very few.
Our suggestion of 95% prediction intervals to help assess replication is meant
to establish a conceptual framework and motivate researchers to simply begin
considering what is a reasonable expectation for a replicated effect. Extending
these concepts to modern study designs is the next step in auditing the conduct
of scientific research.
5.7 Methods
5.7.1 Calculating a 95% Prediction Interval
Comparing 95% Confidence Interval Calculation to 95% Prediction
Interval Calculation
Suppose we observe data X1, . . . , Xn from a normal distribution with mean µ
and variance σ2, with σ2 known. Then by the Central Limit Theorem, X̄ ∼





∼ N(0, 1). We can state that P (−z0.975 < Z <
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z0.975) = 0.95. This leads to the following arithmetic:






< z0.975) = 0.95
P (−X̄ − z0.975
σ√
n




P (X̄ − z0.975
σ√
n




Hence, we state the 95% confidence interval for µ as X̄ ± z0.975σ/
√
n.
Contrast this with the procedure with constructing a 95% prediction inter-
val for Xn+1, another observation from the original normal distribution. From
above, Xn+1 ∼ N(µ, σ2) and X̄ ∼ N(µ, σ2/n). Since both are normally dis-
tributed, we are able to state the distribution of their difference: X̄ −Xn+1 ∼






We can run through a series of similar arithmetic as above to isolate Xn+1 and
produce the 95% prediction interval for Xn+1 as X̄ ± z0.975σ
√
1 + 1/n. Notice
that in the calculation of the prediction interval, both the variability of the ob-
served sample X1, . . . , Xn as well as the variability of the new observation Xn+1
come into play.
Note that the 95% confidence interval for the true difference (here µ−µ = 0)
is X̄−Xn+1± z0.975σ
√
1 + 1/n, and that this is referring to a population differ-
ence of zero. Let us suppose that once this confidence interval is constructed,





1 + 1/n > 0
(X̄ −Xn+1) + σ
√
1 + 1/n > 0




1 + 1/n > Xn+1
X̄ + σ
√
1 + 1/n > Xn+1
A similar argument can be made if zero is outside and strictly above the
95% confidence interval for the difference. Hence, the new observation Xn+1
falls inside the 95% prediction interval if and only if zero, the true population
difference, falls inside the 95% confidence interval for the difference.
95% Prediction Interval for Correlation Coefficients
We calculate a prediction interval based on the original rorig and replication
rrep correlation estimates. Under normality and independence assumptions, the
Fisher z-transformation provides the relationship:





















Assume that r̂orig and r̂rep are the estimates from the original and replication
studies and assume they have a common value. Then, we make the conservative
assumption that the original and replication experiments are independent, we
can calculate:


















(ẑforig − ẑfrep) ∼ N(0, 1)




(ẑforig − ẑfrep) < z1−α/2) = 1− α
P (−ẑforig − z1−α/2setotal > −ẑfrep > −ẑforig + z1−α/2setotal) = 1− α
P (ẑforig − z1−α/2setotal < ẑfrep < ẑforig + z1−α/2setotal) = 1− α
So a (1 − α)% prediction interval for zfrep is ẑforig ± setotalz1−α/2. We can




To simulate, we took all reported correlation coefficients for original studies. As











. We set ρ = r̂orig, and sim-












where nrep was the sample size of each replication experiment. If nrep was un-
available, we used norig, and if both were unavailable, we used the median of
the original sample sizes. If r̂orig was unavailable, we similarly used the median
of the correlations coefficients for the original studies.
Once we had 10,000 realizations from the distribution of the replicate correla-
tion coefficients, we back-calculated them into F-statistics. We used the formula














10,000 F-statistics, we were able to calculate 10,000 P-values and count up how
many were < 0.05
We made two assumptions/simplifications in the course of running this sim-
ulation, as it is merely for illustrative purposes. (1) We assumed that the corre-
lation coefficient reported for the original study represented the true, population
correlation coefficient (2) we converted all simulated correlation coefficients to
F (1, df2) statistics, where df2 were the degrees of freedom from the size of the
replication study. Since 70% of the original studies conducted the same analysis,
we felt that this was a reasonable simplification for comparative purposes.
5.7.3 Code
Code and data to reproduce this analysis is available from:
• https://github.com/jtleek/replication paper
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Figure 5.2: Empirical probability of replicating by effect size. We
simulated 10,000 effects from a distribution that assumes the original study
effect is true. These were converted to test statistics, for which P-values were
calculated. We then colored each point from Figure 3 in the original paper by
how many times the calculated P-value was < 0.05 out of the 10,000 simulations.
This corresponds to the empirical probability of each study “replicating” by

























In predict ion interval
Below predict ion interval
Above predict ion interval
Figure 5.3: Sample sizes of studies in the Reproducibility Project col-
ored by whether they fell in the 95% prediction interval. A plot of the
original versus replication sample size colored by whether the resulting replica-
tion effect was inside (grey), above (blue) or below (pink) the 95% prediction




In this compendium of work, we have proposed a set of novel approaches for
building and investigating genomic signatures. All of these proposals have been
made with downstream clinical impact in mind. Specifically, we examined is-
sues in reproducibility, replicability, and additional value provided by genomic
prediction.
We first described an issue in the reproducibility of predictions from existing
gene signatures based on gene expression information. In introducting “test
set bias”, we illustrated how necessary steps in normalization and data pre-
processing depend upon the size and characteristics of the test set of patients
upon which we are applying the predictive model. We applied the PAM50
subtyper to a real breast cancer data set and showed that patients in subsamples
of different sizes or proportions of Estrogen Receptor negative patients may
receive a different subtype assignment than they did when processed with the
entire data set. Since this is simply a technical context change and not a true
biological change in the patient, we deem this to be problematic and suggest
rank-based prediction as an alternative that can avoid this form of bias.
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We then suggested a novel signature-building method that uses rank-based
features (Top-Scoring Pairs) as primary predictors in a decision tree. These
choices are motivated by our desire to make the entire signature-building pro-
cess more transparent, interpratable, and reproducible. We described “empir-
ical controls” and conditional feature addition via regression as filtration and
wrapper steps unique to Top-Scoring Pair selection. We compared a small de-
cision tree built from our method that relies on fewer than ten genes to the
MammaPrint signature, which relies on seventy genes, and showed that the
performance of our signature was comparable on the original MammaPrint val-
idation data. To ensure reproducibility and transparency of the procedure, we
described the tdsm R package, which provides templated data analyses with
user input as the only parameter.
Supposing that we have built a genomic signature that does not succumb
to “test set bias” and is well-defined and interpretable, the question remains of
how much additional value a prediction from this signature would provide above
what a doctor already knows when a breast cancer patient is examined in the
clinic. To address this question, we proposed the use of covariate adjustment
techniques in the realm of randomized clinical trials. We described a class
of adjusted estimators that provide as much or more precision (small variance)
when compared to the standard, unadjusted average treatment effect estimator.
We leveraged the fact that we can estimate precision gain due to covariate
adjustment to test different sets of covariates in a trial simulation based on real
data with exogenous assigned treatment. Of specific interest was comparing
the relative gain due to adjusting for a set of only clinical covariates (Age,
ER Status, Tumor Size, Tumor Grade) to the same set with the MammaPrint
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prediction included. We showed that an additional 1-2% gain in precision can
be attributed directly to the prediction from MammaPrint.
Finally, we described the issue of replicability of a scientific study through
an example in the psychology literature. We suggested 95% prediction intervals
as a method to establish expectations of a plausible range of values within
which a replicated finding could reasonably fall. We used this approach to
provide context to a recent study on replicability in psychology and were able
to assure that most of the replicated effects fell within a plausible range when
the variability in both the original study and the replication were taken into
account. We included this work in reference to genomic signatures to emphasize
the need for multiple validation studies for confirmation of an association.
Public Health Impact
The goal of this work is to improve the standing of genomic predictors in clinical
use. By assessing their reproducibility, replicability, and value, we hope that
signatures produced in the future will be more reliable, consistent, and trust-
worthy. Assuming that the underlying relationship between genomic features
and the outcome of interest is informative, we hope that these improved sig-
natures have greater potential to be part of the standard of care for patients.
For cancer patients, a genomic test may be less invasive than a tumor biopsy
or other standard clinical technique, so if tests based on genomics are truly
providing additional value in a reliable manner, there is great opportunity to








7.2.1 Proof of t-statistic equivalency when regression is
flipped











β1 β0 β2 β3
]
, H = I − Z(Z ′Z)−1Z ′. We organize β as
stated so that β1 is the multiple regression coefficient for X. We establish a
partial least squares regression as follows:
Y = Dβ′ + ε
HY = HDβ′ +Hε
eY |Z = eX|Zβ1 + ε
∗
Here, eY |Z is the vector of residuals from regressing Y on Z. We will then use
the least squares solution for β1 in terms of residuals, and recall the definition






cov(eX|Z , eY |Z)
var(eX|Z)
=





where ρX,Y |Z is the parital correlation coefficient for X and Y given Z, by
definition the correlation of the residuals above.
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(eY |Z − êY |Z)2
(n− p)(n− 1)var(eX|Z)
In the above equation, we must set p to the number of parameters in the original
multiple regression, Y = Dβ′, to ensure proper calculation of the variance.
Combining the first two steps, we have the expression for the t-statistic for
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where r is the corresponding correlation coefficient. So the final term in the ex-











(eY |Z − ēY |Z)2
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1− ρ2X,Y |Z =
√
(n− p)ρX,Y |Z
t2X(1− ρ2X,Y |Z) = (n− p)ρ2X,Y |Z
t2X = (n− p)ρ2X,Y |Z + t2Xρ2X,Y |Z
ρ2X,Y |Z =
t2X
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and the corresponding equation X = FΓ′ + δ,
we are able to equate the corresponding t-statistic for Y , tY , by noting that
ρX,Y |Z = ρY,X|Z :
t2X
t2X + (n− p)
=
t2Y
t2Y + (n− p)
t2X(t
2










Since the correlation coefficient relationship ρX,Y |Z = ρY,X|Z implies that
both have the same sign,
tX
√
t2X + (n− p)
must have the same sign as the cor-
responding expression for tY . The denominators in both equivalent expressions
must be positive, so the numerator determines the sign of the expression. It
follows that tX = tY .
7.3 Appendix C
7.3.1 Data Sets GSE19615, GSE11121, GSE7390
The three datasets GSE19615, GSE11121, GSE7390 are available from the Gene
Expression Omnibus [26]. We obtained the datasets using the MetaGX package
in R (available at https://github.com/bhaibeka/MetaGx). Their key character-
istics are summarized in Tables 7.1–7.3 below. In our analyses, we dropped the
two patients in GSE7390 whose tumor grade was unknown.
7.3.2 MammaPrint Prediction
We used the genefu package in R [38] to make MammaPrint predictions using
the gene expression data supplied with each dataset described in Section 1.
We specifically used the gene70 function, which takes as input the expression
data matrix and gene annotations and provides as output both a continuous
risk score and the dichotomized risk classification. We used the latter as the
MammaPrint risk covariate in our covariate adjustment steps. For each dataset,
we used the same covariate setsW−ER,WC ,WG,WCG for adjustment, as defined





















Table 7.1: Characteristics of dataset GSE19615. ER - estrogen receptor
status, Grade - tumor severity grading (3 is most severe), Five-Year Recurrence
- whether or not cancer has reappeared after five years, MammaPrint risk pre-
diction - high or low risk for cancer recurrence. Age and Tumor Size are given





















Table 7.2: Characteristics of dataset GSE11121. ER - estrogen receptor
status, Grade - tumor severity grading (3 is most severe), Five-Year Recurrence
- whether or not cancer has reappeared after five years, MammaPrint risk pre-
diction - high or low risk for cancer recurrence. Age and Tumor Size are given





















Table 7.3: Characteristics of dataset GSE7390. ER - estrogen receptor
status, Grade - tumor severity grading (3 is most severe), Five-Year Recurrence
- whether or not cancer has reappeared after five years, MammaPrint risk pre-
diction - high or low risk for cancer recurrence. Age and Tumor Size are given
as means with standard deviations in parentheses.
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7.3.3 Differences between unadjusted and adjusted esti-
mators
To assess how different the estimators computed under the unadjusted and ad-
justed cases are, we looked at the difference ψ̂juna−ψ̂jadj over the j = 1, . . . , 100, 000
iterations in each of the four simulations using the four datasets in our study.
A histogram of the differences for the simulation using the MammaPrint vali-
dation dataset is presented in the main manuscript. Three histograms for the
simulations using GSE19615, GSE11121, and GSE7390 appear in this supple-
ment, below. We also present in Table 7.4 a comparison across all four studies
of the average difference, the standard deviation of the difference, and the per-
centage of times that the unadjusted estimator was larger in absolute value than
the adjusted estimator. Since the true treatment effect was set to zero in each
simulation study, if the adjustment covariates are prognostic of the outcome, we
would expect the adjusted estimator to be closer to zero more often than the
unadjusted estimator. This occurred in over 50% of the iterations in all four
studies. In all cases, we used the estimators adjusted for all available covariates
(clinical + genomic).
7.3.4 Variation in magnitude of precision loss when co-
variates are not prognostic
We presented in Table 4.3 of the main text the loss in precision due to adjust-
ment when data was generated from a distribution with W and Y independent.
We used more covariates than are usually recommended for this procedure be-
cause we wanted to include all clinically relevant baseline covariates that are
usually measured for a breast cancer patient. We found that the sample size
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Figure 7.2: Histogram of ψ̂juna− ψ̂jadj, GSE19615. The histogram of differ-
ences between the unadjusted and adjusted estimators is roughly normal and
is centered close to zero (mean=-6.7e-07, standard deviation=0.05). The un-
adjusted estimator is larger in absolute value than the adjusted estimator in
approximately 55% of simulations.
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Figure 7.3: Histogram of ψ̂juna− ψ̂jadj, GSE11121. The histogram of differ-
ences between the unadjusted and adjusted estimators is roughly normal and
is centered close to zero (mean=-4.6e-05, standard deviation=0.0242). The un-
adjusted estimator is larger in absolute value than the adjusted estimator in
approximately 53% of simulations.
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Figure 7.4: Histogram of ψ̂juna − ψ̂jadj, GSE7390. The histogram of differ-
ences between the unadjusted and adjusted estimators is roughly normal and
is centered close to zero (mean=0.0001, standard deviation=0.0219). The un-
adjusted estimator is larger in absolute value than the adjusted estimator in
approximately 51% of simulations.
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Dataset mean(ψ̂juna − ψ̂jadj) SD(ψ̂juna − ψ̂
j
adj) % |ψ̂juna| > |ψ̂
j
adj|
Mammaprint 5.4e-05 0.0145 53.1
GSE19615 -6.7e-07 0.05 55.2
GSE11121 -4.6e-05 0.0242 52.8
GSE7390 1.3e-04 0.0219 51.0
Table 7.4: Differences between unadjusted and adjusted estimators
We find that the average difference between the unadjusted and adjusted esti-
mators is similar across all simulations and the standard deviations are compa-
rable, although the standard deviation in GSE19615 is more than twice as large
as the others. The final column in the table shows the percentage of simulation
iterations in which the adjusted estimator was closer in absolute value than the
unadjusted estimator to the true treatment effect of zero. For each dataset, this
occurred in slightly more than 50% of the iterations.
Original Sample Size
Covariate Set σ2una σ
2
adj Gadj
W−ER 0.00178 0.00180 -1.1%
WC 0.00178 0.00181 -1.5%
WG 0.00178 0.00179 -0.4%
WCG 0.00178 0.00181 -1.8%
Table 7.5: Precision gains under data generating distribution
with W and Y independent, based on marginal distributions from
Mammaprint validation data set, using fewer clinical covariates.
in the simulated trials and the number of covariates we included affected the
magnitude of precision losses. To illustrate, we conducted additional simulation
studies where W and Y are independent, both using the MammaPrint valida-
tion dataset, where we used fewer adjustment covariates as shown in Table 7.5.
Specifically, we defined new covariate setsW ′−ER ={Tumor Size},W ′C = {Tumor
Size, ER status}, W ′G = {MammaPrint Risk Prediction}, W ′CG = {Tumor Size,
ER status, MammaPrint Risk Prediction}. The precision losses were smaller in
magnitude when we reduced the number of adjustment covariates in this way.
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With Jeff Leek,
• Identified and described bias due to data normalization in the prediction of
breast cancer subtypes using gene expression information.
• Formalized feature selection and modeling with Top-Scoring Pairs for simple,
decision-tree-based classifiers.
• Developed R packages for standardized analysis templating (tdsm) and inter-
active health visualizations (healthvis).
• Suggested 95% prediction intervals as a means of assessing whether a study
result has been replicated.
With Jeff Leek and Michael Rosenblum,
• Used RCT baseline covariate adjustment methods to assess the additional value
a genomic prediction can provide beyond standard clinical measurements in
improving the precision of a treatment effect estimator.
• Examined the benefit of using machine learning methods to summarize the
predictive value of large numbers of baseline covariates in an RCT setting.
Scientific Programmer 2009-2011
Center for Biomedical Informatics, Harvard Medical School, Boston, MA
• Developed synthetic patient simulation platform predicated on Bayesian net-
works, and accompanying web service.
• Built clinical trial simulation framework using synthetic patients, stochastic
PK-PD models for drug clearence, and coded clinical trial protocols.
• Fosterd collaboration with Beth Israel Deaconess Medical Center and Genome-
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day-to-day lab operations and omics pipeline deployement.
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School to develop an open-source pipeline using next-generation sequencing
(NGS) technology to detect and clincally annotate all variants in an individual
human genome.
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Hadoop/MapReduce.
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* - Presenter
TEACHING Guest lecturer, BIO622 2015
Conducted daily lecture for 500+ student course
Lead TA, BIO621-623 2014-2015
Prepared and held 2-3 sections per week, 40-60 students each
Beta-tested, proctored, and graded exams
TA, BIO611-612, 615, 621-624, AS.280.35 2012-2014
Graded homework and exams, held small sections and office hours
SERVICE Refereeing: Biometrics, Genome Biology, PLOS ONE
Organization
• Session chair, Next Generation Sequencing. ENAR 2014.
• Organizer (2012), Hopkins Biostatistics Computing Club.
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AWARDS Jane and Steve Dykacz Award 2016
Departmental award for best student paper in medcial statistics
Awarded for “Genomic and clinical predictors for improving estimator
precision in randomized trials of breast cancer treatments”
Helen Abbey Award 2016
Departmental award for teaching
JHSPH Student Assembly Teaching Assistant Recognition Award 2015
One of two voted on by students across all courses in JHSPH
NYU Honors Scholar 2008
NYU Deans List 2006-2007
National Merit Scholarship 2005-2008
SOFTWARE R Packages (submitted to Bioconductor):
healthvis (https://github.com/prpatil/healthvis)
Interactive health visualizations. Built using d3, shiny, htmlWidgets.
tdsm (https://github.com/prpatil/tdsm)
Templated Deterministic Statistical Machines. Automated analysis templates
and standardized reports that can be edited and compared.
Languages:
R, Javascript, C/C++, Java, Perl, MATLAB, Stata, Hadoop, Shell scripting
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